Adial Pharmaceuticals, Inc. — Q3 2023 Form 10-Q
Reporting period: Three and nine months ended September 30, 2023; filed November 14, 2023. Adial is a clinical-stage biopharmaceutical company developing AD04 for alcohol use disorder (AUD). It has no approved products and has not generated significant product revenue.
Financial performance and position
- Revenue: No significant product revenue reported.
- Q3 2023: Operating expenses were $1.36 million, down from $2.55 million a year earlier. Continuing-operations loss was $1.35 million versus $2.55 million; net loss was $1.38 million versus $3.11 million.
- Nine months: Operating expenses were $5.10 million, down from $8.26 million. Continuing-operations loss was $5.10 million versus $8.25 million. Net loss was $3.20 million versus $9.86 million, reflecting a $2.62 million gain on the Purnovate sale; the prior-year period had a $1.62 million discontinued-operations loss.
- Cash flow, nine months: Operating cash used was $5.58 million, compared with $9.44 million in 2022; investing cash provided was $1.15 million, principally from the Purnovate sale; financing cash provided was $0.75 million, versus $9.13 million. Cash decreased by $3.69 million.
- Liquidity and liabilities: Cash and cash equivalents were $315,880 at September 30, versus $4.00 million at December 31, 2022. Current assets were $1.14 million and current liabilities $528,179. Total liabilities were $528,179; the balance sheet reports no debt. Stockholders’ equity was $2.34 million.
- Margins: Not meaningful to report given the absence of significant product revenue.
Material changes and significant events
- Adial sold Purnovate’s assets to Adovate, a related party whose CEO and major equity holder is a former Adial director and CEO. Consideration was reported at $3.23 million, including $1.73 million in Adovate equity, $800,000 cash and $700,000 in expense reimbursements receivable. The transaction generated a $2.62 million gain.
- Adial received a 19.9% equity stake in Adovate, carried at $1.73 million, and reported a $350,000 reimbursement receivable still due. The filing says a further $350,000 payment was due by December 2, 2023.
- On October 19, 2023, after quarter-end, Adial completed a private placement of pre-funded and other warrants for approximately $4.0 million gross proceeds; net proceeds were expected to be about $3.5 million.
- Adial effected a 1-for-25 reverse stock split on August 4, 2023. Shares outstanding were 1,217,981 at September 30.
Outlook, risks and other matters
- Going concern: Management said September 30 cash was insufficient to fund operations for the next 12 months from filing, raising substantial doubt about the company’s ability to continue as a going concern. Management expected the post-quarter financing, the remaining Adovate reimbursement and shared-services payments to support basic operations for roughly a year, but not additional AD04 development or contingencies.
- Development funding: Adial’s planning assumption is two further Phase 3 trials for AD04, estimated to cost approximately $25 million in total. The company was in discussions with potential commercial partners. Additional capital is required, and no assurance was given that financing or partnerships would be available on acceptable terms.
- Development and regulatory uncertainty: AD04’s ONWARD Phase 3 results were released in 2022; Adial said it was engaging with U.S. and European regulators on next steps. Commercialization, if successful, was not expected before 2026 or later. Clinical, regulatory, manufacturing, financing and competition risks remain.
- Nasdaq listing: Although the company reported regaining compliance with the minimum bid-price and stockholders’ equity requirements earlier in 2023, September 30 equity of $2.34 million was below Nasdaq’s stated $2.5 million minimum. Nasdaq was monitoring compliance, creating potential delisting risk.
- Controls: Management identified material weaknesses in internal control over financial reporting and concluded disclosure controls and procedures were not effective at period-end. Management nevertheless stated the financial statements fairly present the company’s financial condition and results.
- Other: No pending material legal actions were reported. The filing disclosed related-party consulting arrangements and approximately $302,000 of future cash commitments under other consulting and vendor agreements.
Most important facts for investors to verify
- Whether the October financing closed on the stated terms and the company received the expected net proceeds.
- Whether Adovate paid the remaining $350,000 reimbursement and made shared-services payments as expected.
- Adial’s current cash runway, operating plan and ability to fund AD04’s estimated $25 million of further trials.
- Regulatory feedback and any concrete trial, partnering or commercialization milestones for AD04.
- Nasdaq listing compliance status and progress remediating the disclosed material weaknesses.
- Valuation and performance of the Adovate equity investment, and the status of any contingent sale payments or royalties.